Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age

PURPOSE: To compare refractive and biometric outcomes in patients with type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of ranibizumab (IVR) versus bevacizumab (IVB), at a corrected age of 3 years. METHODS: A retrospective case series compared cycloplegic refractive status...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yen-Chih, Chen, San-Ni, Yang, Benjamin Chi-Lan, Lee, Kun-Hsien, Chuang, Chih-Chun, Cheng, Chieh-Yin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866885/
https://www.ncbi.nlm.nih.gov/pubmed/29713524
http://dx.doi.org/10.1155/2018/4565216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866885/
https://www.ncbi.nlm.nih.gov/pubmed/29713524
http://dx.doi.org/10.1155/2018/4565216

Ejemplares similares